Open Calls for Proposals

Consortia of minimum of 3 (and a maximum 6) partners from at least 3 different eligible countries (see in the call)

Aims of the call:

The anticipated outcome of the call is the development of innovative, personalised approaches for cancer diagnosis, patient stratification, and treatment, grounded in a deeper mechanistic understanding of metabolic alterations in cancer.

Proposals must address at least one of the aims:

Aim 1: Enabling better cancer diagnostics and monitoring through metabolic biomarkers

Novel metabolic biomarkers and technologies offer major opportunities for earlier cancer detection, improved patient stratification and more accurate monitoring of treatment response and disease progression.

Aim 2: Intercepting metabolic vulnerabilities to improve precision medicine

Metabolic reprogramming in cancer creates unique dependencies that can be exploited therapeutically. Tumours often develop distinct metabolic signatures, shaped by oncogenic mutations, which drive tumour initiation, progression, therapy resistance, and metastasis. These metabolic adaptations open the door to precision medicine approaches that target defined metabolic vulnerabilities with tailored interventions.

Funding for the Israeli partner: up to 140K Euro for 3 years (160K Euro for coordinator).
* A short abstract and budget should be sent to the Ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272, 1588). 

https://transcan.eu/news-and-resources/updates/preliminary-announcement-upcoming-call-jtc-2026.kl

האגודה למלחמה בסרטן: קול קורא להגשת הצעות מחקר

מענקים לחקר מחלות סרטן:

• מחקר קליני ובסיסי בעל פוטנציאל ליישום קליני
• עדיפות למחקר המשלב אספקטים קליניים ובסיסיים
• מחקר אפידמיולוגי ואפידמיולוגי- גנטי
• רפואה מותאמת אישית – Personalized medicine

מימון: 180,000 ₪ למשך שנתיים.

שיתוף פעולה עם חוקר הולנדי – 180,000 ₪ לשנתיים. יש לצרף לעותק הבקשה המקורי מכתב שת”פ בחתימת החוקר וציון שיוכו האקדמי.

שימו לב: אין כיסוי לתקורה.

האגודה מעודדת עבודות מחקר בנושאים הקליניים, ההתנהגותיים והאפידמיולוגים, ומעודדת מחקרים קליניים ובסיסיים המבוצעים ע”י רופאים המטפלים בחולים.

עדיפות להצעות בעלות פוטנציאל ליישום קליני, שתתבססנה על שיתוף פעולה בין רופאים לחוקרים במדעי היסוד. וכן להצעות מחקר שתוגשנה ע”י רופאים.

מענקי מחקר בסרטן 2027 – קול קורא לחוקרים – האגודה למלחמה בסרטן

עמותת “לראות” – קול קורא למענקי מחקר בתחום העין והראיה

העמותה תתמוך בשני מענקי מחקר (אחד קליני ואחד בסיסי) לאבחון קליני/ גנטי ו/או טיפול במחלות עיניים, עם יתרון למחלות שכיחות בישראל, הגורמות לאובדן משמעותי בראיה (למשל מחלות רשתית ניווניות תורשתיות, ניוון מקולרי גילי, גלאוקומה, מחלות עצב, רטינופתיה סוכרתית ועוד), ולטיפולים שלהם תהא השפעה פוטנציאלית על מספר רב ככל האפשר של מטופלים. כמו כן, תתקבלנה הצעות מחקר בסיסי-קליני שעשויות להוביל להבנה טובה יותר של המחלות ולטיפול בהן בעתיד.

– תינתן עדיפות למחקרים שיש בהם שת”פ משמעותיים בין שני חוקרים לפחות.

מימון: 100 אלף ₪ לכל מענק למשך שנה אחת.

https://trdf.technion.ac.il/wp-content/uploads/2026/07/LIROT-call.pdf

RA mandatory submission: 6.8 | MOST submission: 13.8

German and Israeli scientists are invited to submit joint pre-proposals for innovative and potentially applicable research projects on all topics and aspects (prevention, diagnosis, therapy) related to the full range of state-of-the art cancer research (basic research/discovery/innovation to preclinical translation/validation and clinical translation). The potential for cancer therapy should be clearly pointed out. Clinical trials are not suited for this program.
Funding: up to 43K EUR (172K NIS) per year for 3 years. 6 joint projects will be funded.

If interested, please contact the research authority to check your eligibility.

https://www.gov.il/he/pages/rfp111062026

Stage 1: short proposal, Stage 2: Support phase, invited Stage 3: Full proposal
To support multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Priority areas: paediatric rare diseases; rapidly progressive rare diseases; and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments.
* Each consortium must designate a Clinical Trial Sponsor and a Coordinating Investigator, include at least one funded patient partner (via a PAO or other organised patient group), and secure access to a qualified multinational Clinical Trial Management Organisation (CTMO).
Only multinational trials will be funded (minimum of three independent eligible partner institutions from at least three different eligible countries; PAOs focused primarily on PPIE do not count towards this minimum).
https://erdera.org/call/ctc2026/
Information webinar: 6 July 2026, 15:00–17:00 CEST. More information and registration: https://erdera.org/event/erdera-clinical-trial-call-2026-information-webinar/.

The goal of this program is to generate large-scale, high-resolution proteoform datasets across Parkinson’s-relevant brain regions and matched biofluids to enable biomarker discovery and support the development of accessible, clinically meaningful fluid-based biomarkers.

This program supports two complementary funding tracks: 

1. Global Proteoform Profiling: A broad, proteome-wide effort to systematically characterize proteoforms, addressing a critical gap where conventional proteomics fails to capture disease-relevant molecular forms.
2. Tau Proteoform Characterization: A focused track on Parkinson’s-relevant proteoforms of tau, addressing the limited understanding of tau biology in Parkinson’s disease.

Applicants may apply to both tracks but must submit separate applications.

Funding: Up to $1M over 2 years.

Information Sessions: Register online to learn about the program and to ask your questions.

https://forms.cloud.microsoft/r/4UeNwMGVzt

www.michaeljfox.org/funding-opportunities

Translational Research Award: Supports high-impact translational research that will accelerate critical findings into clinically relevant solutions.

Funding: up to $800K for 3 years.

Clinical Research Award: Supports clinical research that evaluates disease specific factors and interventions. Funded research should generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy.

Funding: up to $3.25M for 4 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719108

https://ebrap.org/eBRAP/public/Program.htm

The Barancik Prize recognizes an exceptional scientist or a team of scientists whose work in MS research demonstrates outstanding innovation and originality. The winner receives a $125,000 prize, to be used at the discretion of the recipient, and a $200,000 fellowship award for a trainee at the recipient’s institution.

The prize is administered by the National Multiple Sclerosis Society. A selection committee comprised of leaders in science, medicine, and MS advocacy will review nominees and evaluate:

• Exceptional innovation and originality in MS scientific research
• Impact and potential of the research to lead to pathways for the treatment and cure for MS
• Scientific accomplishments that merit recognition as a future leader in MS research

The award is intended for early to mid-career MS researchers. Nominees should have no more than 20 years of experience as an independent investigator to be eligible.

https://www.nationalmssociety.org/for-professionals/for-researchers/research-funding-opportunities/awards-prizes/barancik

The Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis-driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the research community.

The GBA1-PD Research Catalyst Program supports: 

• Hypothesis-driven studies that define the molecular mechanisms linking GBA1 dysfunction to neurodegeneration, including interrogation of lysosomal biology, lipid metabolism, and alpha-synuclein dynamics, as well as investigations into variant-specific effects and the biological basis for disease specificity in Parkinson’s disease versus Gaucher disease.
• Research aimed at identifying modifiers of penetrance, progression, and clinical heterogeneity in GBA1-PD, leveraging existing longitudinal cohorts, multi-modal datasets, and cross-cohort analyses to uncover genetic, molecular, and environmental drivers of disease variability.
• Studies that characterize cell-type–specific and systems-level effects of GBA1 dysfunction, including work in neurons, glia, and peripheral systems, alongside efforts to rigorously evaluate, benchmark, and standardize preclinical models to improve translational relevance and reproducibility.

Funding: Up to $300,000 over 2 years.

www.michaeljfox.org/funding-opportunities

https://everycat.org/wp-content/uploads/2026/04/2026-Fall-EveryCat-Health-Foundation-RFP-Final.pdf

Clinical Translational Research Award (CTRA): Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).

Funding: up to $1.9M for 3 years.

Exploration-Hypothesis Development Award (EHDA): Supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the TSC research field.

Funding: up to $0.35M for 2 years.

Idea Development Award (IDA): Promotes ideas that have the potential to yield high-impact findings and new avenues of investigation.

Funding: up to $0.8M for 3 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=713103

https://ebrap.org/eBRAP/public/Program.htm

Applications submitted to the FY26 PRMRP must address one or more of the following congressionally mandated topic areas:

Accelerated Aging Processes Associated with Military Service | Angelman Syndrome | Burn Pit Exposure | Brain Injury Impact on Cardiac Health | Celiac Disease | Congenital Cytomegalovirus | Dystonia | Eating Disorders | Eczema | Ehlers-Danlos Syndrome | Endometriosis | Facioscapulohumeral Muscular Dystrophy | Fibrous Dysplasia/McCune-Albright Syndrome | Food Allergies | Fragile X | Frontotemporal Degeneration | Gambling Addiction | Hepatitis B | Hereditary and Acquired Ataxia | Hereditary Hemorrhagic Telangiectasia | Hermansky-Pudlak Syndrome | Hydrocephalus | Hypertrophic Dyschromia | Hypoxia | Infertility Associated with Military Aviators and Aviation Support Personnel | Inflammatory Bowel Disease | Interstitial Cystitis | Intranasal Ketamine Anesthetics | Maternal Mental Health | Mitochondrial Disease | Musculoskeletal Health | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Myotonic Dystrophy | Orthotics and Prosthetics Outcomes | Pancreatitis | Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus | Peripheral Neuropathy | Polycystic Kidney Disease | Post-Traumatic Stress Disorder | Prader-Willi Syndrome | Proteomics | Pulmonary Fibrosis | Respiratory Health | Rett Syndrome | Sarcoidosis | Scleroderma | Sickle-Cell Disease | Sleep Disorders and Restriction | Spinal Muscular Atrophy | Suicide Prevention | Tuberculosis | von Hippel-Lindau Syndrome

Clinical Trial Award (Preproposal): Supports the rapid execution and analysis of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.

Funding: up to $20M for 4 years. .

Impact Award (LOI): Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research and insights from the real-world environment to foster clinical applicability.

Funding: up to $3.6M for 4 years.

Lifestyle and Applied Health Research Award (LOI): Supports clinical research and/or clinical trials using a combination of scientific disciplines, including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health.

Funding: up to $4.2 for 4 years.

Platform Clinical Translation Award (Preproposal): Supports the translational development and/or earlyphase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two FY26 PRMRP topic areas.

Funding: up to $15M for 4 years.

Technology/Therapeutic Development Award (LOI): Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.

Funding: $5.6M for 4 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719111

https://ebrap.org/eBRAP/public/Program.htm

Career Development Award: Supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct innovative, high-impact ideas or early-phase, proof-of-principle clinical trials with the potential to have a major impact on autism

Funding: up to $750K for 3 years.

Clinical Trial Award: Supports rapid execution and analysis of clinical trials with the potential to have significant impact on the treatment or management of autism. Funding: up to $1.75M for up to 4 years.

Idea Development Award: Supports the development of innovative, high-risk/highreward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals.

Funding: up to $750K for 3 years

https://cdmrp.health.mil/funding/arp

Clinical Trial Award: Supports the rapid implementation of clinical trials of new interventions for service-related eye injury or visual dysfunction.

Funding: up to $2.6M for 4 years.

Investigator-Initiated Research Award: Funding: up to $1.2M for 3 years.

Translational Research Award: Supports translational research that that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance.

Funding: up to $1.6M for 3 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719107

https://ebrap.org/eBRAP/public/Program.htm

Concept Award: Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

Funding: up to $120K for 1 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/kcrp

Idea Award: Supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus.

Funding: up to $300K for 2 years.

Impact Award: Supports high-risk/high-reward research that has the potential to make a major impact in lupus research and/or lupus disease.

Funding: up to $1M for 4 years.

Transformative Vision Award: Supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study.

Funding: up to $250K for 2 years.

Transformative Vision Development Award: supports interventional research at the individual and/or health care system level, which will result in near-term impact on the health-related quality of life of persons living with lupus.

Funding: up to $1M for 4 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719112

https://ebrap.org/eBRAP/public/Program.htm

Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to significantly impact multiple sclerosis.

Funding: up to $2M for 4 years.

Early Investigator Research Award: Supports multiple sclerosis-focused research opportunities for individuals in the early stages of their careers..

Funding: up to $300K for 2 years.

Exploration – Hypothesis Development Award: Supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study.

Funding: up to $250K for 2 years.

Investigator-Initiated Research Award: supports interventional research at the individual and/or health care system level, which will result in near-term impact on the health-related quality of life of persons living with lupus.

Funding: up to $1M for 3 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=713102

https://ebrap.org/eBRAP/public/Program.htm

For pioneering research leading to greater understanding, prevention, and treatment of age-related macular degeneration.
New Investigator Grant Program
To support investigators during their early years as an independent investigator involved in studies that have an impact on the causes and/or treatment of macular degeneration. Restricted to new and early investigators who have received their MD, PhD or equivalent degree within the past 10 years at the time of application.
Funding: $150K per year (max $450K) for up to 3 years
Standard Award Program
For investigators greater than 10 years post-terminal degree who are appropriately trained to lead an independent research study (basic, translational and/or clinical in nature) that has an impact on the causes, prevention, and/or treatment of macular degeneration.
Funding: $150K per year (max $300K) for up to 2 years
https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/macular-degeneration-research-request-for-proposals/

Projects may be discovery focused, where novel research ideas are tested, or proof of concept studies aiming to generate preliminary data for subsequent applications. Also provide funds for small translational projects that show potential and may pave the way for future major research. Applicants must demonstrate that they have considered how the project may result in patient benefit or clinical application, irrespective of timescales.
* Applications from younger academics, who do not have a tenured position are encouraged.
Funding: Funding is usually capped at £35K, however, this may be increased to £50K in exceptional cases. Applicants should contact us to discuss this prior to submitting an application for that value.
https://www.cclg.org.uk/our-research/research-cclg/researchers/funding-opportunities

Clinical Translation Research Award: up to $2.16M for 3 years

Clinical Trial Award: up to $4.96M for 4 years

Investigator-Initiated Research Award: up to $960K for 3 years

Translational Research Award: up to $2.16M for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719104

Leveraging Research Award: Supports basic, translational and/or clinical research that repurposes or expands existing research resources to accelerate the understanding of PTE and associated comorbidities. • Applications must: o Adapt a cohort, resource, research tool or intervention for which PTE was not a prior focus; o Provide a strong scientific justification for adding PTE-specific cohorts, outcomes, assessments or analyses; and o Demonstrate how this new focus will significantly advance knowledge of the condition.

Funding: up to $800K for 3 years

Virtual Post-Traumatic Epilepsy Research Center (ViP-TERC) – Faulty Award

Solicits faculty members to join the ViPTERC in order to advance PTE research through the development of early-career investigators and investigators new to the PTE field.  • Supports research projects investigating questions across the PTE research spectrum, including biology and etiology, prevention, diagnosis and detection, prognosis, treatment and quality of life.

Funding: up to $800K for 3 years

Virtual Post-Traumatic Epilepsy Research Center (ViP-TERC) – Leadership Award:

Guide the development of successful and highly productive PTE researchers within a collaborative, virtual environment. o Provide Intensive Mentorship: Oversee and facilitate intensive mentoring, national networking opportunities and peer group support for new PTE investigators.  o Foster Collaboration: Facilitate regular, interactive communication and collaboration among all ViPTERC members. o Assess Progress: Track and assess the research outcomes and career progression of the center’s faculty to ensure their success.

Funding: up to $1.6M for 4 years

Idea Development Award: Supports novel, innovative research that has the potential to increase understanding of post-traumatic epilepsy (PTE) and associated comorbidities to improve quality of life, especially in Service Members, Veterans and/or their care partners.

Funding: up to $1M for 3 years

Research Partnership Award: Supports new or existing research partnerships focused on collaboratively addressing critical questions relevant to PTE in a manner that would be unachievable through separate efforts.

Funding: up to $2M for 3 years

https://cdmrp.health.mil/funding/erp

https://cdmrp.health.mil/funding/default

Investigator-Initiated Research Award: Supports studies that further develop mature ideas, expand upon key discoveries, and advance research or patient care for individuals with BMF disease.

Funding: up to $1.25M for 3 years

Idea Development Award: Supports innovative ideas and high impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF).

Funding: up to $800K for 3 years.

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/bmfrp

Coefficient Giving has allocated several million dollars toward the development of better and cheaper alternatives to animal products.  We now see an opportunity to accelerate progress on several fronts, particularly in closing the taste and price gap between alternative proteins and the animal products they aim to replace.

We’re soliciting proposals across four priority areas:

1. Off-flavor reduction in plant- and fermentation-derived protein ingredients, via agricultural, breeding, processing, or fermentation-based interventions;
2. Fat alternatives for flavor generation, including oleogels, emulsion systems on existing margarine/spread lines, oil bodies, novel flavor-active lipid compounds, and oilseed breeding for longer-chain monounsaturates;
3. Egg reduction and replacement through enzymatic approaches, hybrid systems, and foundational functional characterization in industrial bakery, mayonnaise/dressings, and pasta; and
4. Characterizing fish flavors in welfare-priority species, including tilapia and milkfish, carp and bottom-dwellers (including pond loach), and catfish.

Funding: $100,000 to $1 million, over up to 3.5 years.

https://coefficientgiving.org/funds/farm-animal-welfare/request-for-proposals-alternative-protein-rd/

https://docs.google.com/document/d/1rpGC8Wi-LjtXXWgYyF6rOZTRaEwTtnWz2O7RuLjkvUs/edit

Designed to encourage basic research, technological innovation, and informatics pipeline development that can lead to an understanding of blood cancer disease mechanisms, the development of improved methods for detecting and monitoring cancer progression, and the identification of novel therapeutic targets. This is a dedicated mechanism to encourage established investigators to explore the biology of blood cancer and support proof-of-concept studies that could initiate completely novel approaches to treatment.
Funding: up to $250K per year / $750K total for 3 years
https://bloodcancerunited.org/research/grants/discovery-grant-program-dgp

The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research. The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Named for the infant son of preeclampsia survivor Lauren Pappas and her husband Clement, the program seeks to award multiple two-year grants in 2026 totaling up to $200,000.

https://www.preeclampsia.org/research-funding

General Research Grant
Supports basic, translational and clinical research with the goal of advancing therapeutic development in FA.
Funding: up to $125K per year for 1 or 2 years
Postdoctoral Research Award
A mechanism to expand and retain young investigators in the FA biomedical research space. Competitive candidates demonstrate qualities that will enhance FARA’s overall enterprise of understanding fundamentals of disease pathology and developing treatments and a cure for FA.
Funding: up to $100K per year for 1 or 2 years
https://www.curefa.org/research/grant-program/grant-type/#scientist

Funds groundbreaking scientific research that brings us closer to effective treatments and improved care for individuals with Angelman syndrome (AS). The call for research proposals invites scientists and clinicians worldwide to submit innovative studies that align with 2025 ASF Research Roadmap and priorities:

* UBE3A Regulation and Function – rigorous research towards understanding how UBE3A expression is regulated and how UBE3A functions in protein homeostasis and in neuronal function.

* Cutting Edge Therapeutic Strategies – study and development of new therapeutic approaches and the translational

studies required for their advancement to the clinic.

* Clinical Care and Innovation – Enhance the quality of life and well-being of individuals with Angelman Syndrome through comprehensive and personalized clinical care approaches.

* Therapeutic Endpoints and Biomarkers – explore and develop endpoints and biomarkers to improve clinical

trial design and measurement of response beyond physician and caregiver reported measures.  Establish objective measures of treatment response and disease progression to facilitate the evaluation of therapeutic interventions for Angelman Syndrome.

Funding: up to $100,000/year for up to 2 years.

https://angelman.org/call-for-proposals/

Translational Research Award (TRA): Supports mature high-impact translational research that will accelerate innovative ideas into clinical applications, including health care products, technologies and/or practice guidelines.

Funding: up to $1.45M for 2 years

https://cdmrp.health.mil/funding/crrp

https://ebrap.org/eBRAP/public/Program.htm

The PKD Foundation’s principal mission is to support basic, translational, and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD):

• Basic research to enhance understanding of molecular basis of PKD and its pathobiology
• Translational research to accelerate development of predictive and therapeutic strategies for PKD
• Clinical research such as small pilot studies
• Epidemiology/data analysis research to conduct secondary data analyses utilizing existing database resources, or to develop new statistical methodologies or test hypotheses using existing data

The PKD Foundation encourages proposals in the following topic areas:

• Autosomal Recessive PKD (ARPKD)
• ADPKD in children
• The role of cilia signaling in cyst development
• Drug delivery mechanisms
• Epidemiology/ data analysis (e.g., using existing datasets)
• Extra-renal manifestations of PKD, including but not limited to congenital hepatic fibrosis, polycystic liver disease and intracranial aneurysms
• Protein dosage or gene therapies
• Innovative approaches to machine learning
• Lifestyle interventions (e.g., in dietary habits)

Funding: up to $120,000 per year for two years

https://pkdcure.org/research/grants/pkd-foundation-research-rfa

Patient-Centered Outcomes and Survivorship Award: Supports high-risk, high-reward studies that span the spectrum of survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, and co-morbid conditions.

Funding: up to $975K for 3 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719103

https://ebrap.org/eBRAP/public/Program.htm

Clinical Trial Award: Supports clinical trials with the potential to significantly impact the prevention, treatment or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures

Funding: up to $4.5M for 4 years

Investigator-Initiated Research Award:

Supports studies that will make an important contribution to research and/or patient care for diseases or conditions associated with military related toxic exposures.

Funding: up to $800K for 3 years.

Translational Research Award:

Supports translational research that will accelerate the movement of promising ideas in military-related toxic exposures research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research should integrate basic science and clinical observations.

Funding: up to $1.5M for 3 years

https://cdmrp.health.mil/funding/terp

https://cdmrp.health.mil/funding/default

Applied Research Award: Supports applied research, defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies.

Funding: up to $950K for 3 years

Clinical Research Award: Supports clinical research that evaluates orthopaedic-specific factors and interventions; the ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy.

Funding: up to $3.2M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/prorp

Idea Development Award (IDA): Promotes new ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation in the rare cancers field.

Funding: up to $490K for 3 years

Resource and Community Development Award (RCDA): Supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers.

Funding: up to $1.12M for 4 years.

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rcrp

Applicants may submit a pre-proposal application at any time. Pre-proposals will be reviewed by MJFF within three weeks of submission. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal through one of the four review cycles. 

This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.

The Therapeutics Pipeline Program is only open to industry and industry-academia collaborations.

Funding: Award amounts for this program may range from $250,000 for smaller, targeted programs to upwards of $2M for larger, multi-stage preclinical and/or clinical programs

Duration: 1-2 years for pre-clinical programs, 2-3 years for clinical programs

https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program?em_cid=mc-a1bHq00000AbgaK

Mentored Clinical Research Award: Supports clinical research (e.g., research conducted with human subjects, samples, or data of human origin) by a clinician in training under an established mentor. Funding: up to $75K for 1.5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719107

https://ebrap.org/eBRAP/public/Program.htm

An annual award worth €200,000, recognising researchers whose scientific discoveries have had a major impact on the care of patients with cancer.  The Gustave Roussy Prize is awarded each year to a prominent figure in oncology research whose scientific breakthroughs in the fields of cancer diagnosis, treatment, or prevention have significantly improved patient care or led to a better understanding of the disease.  The prize highlights innovation and scientific commitment that led to tangible, lasting benefits for patients, in perfect alignment with Gustave Roussy’s mission: to cure more patients, more effectively and more sustainably. It is endowed with €200,000: €100,000 for the laureate’s free use, and €100,000 to support an innovative research project in oncology.  The Prize is open to researchers of all nationalities. An independent jury of international experts selects the laureate solely on scientific excellence and clinical impact, regardless of discipline or institution.

https://www.gustaveroussy.fr/en/gustave-roussy-prize

In 2026, grants are available in the following areas:

• In-vitro models and assays to identify novel therapies for neuroinflammatory diseases.  To develop predictive in-vitro models aimed at identifying and optimizing novel small molecule medicines for human neuroinflammatory diseases. One grant of up to 500K EUR over 2 years.
• Artificial intelligence in cell culture media and process development. Proposals for robust, host-agnostic, and easy to parameterize models, that enable us to more quickly develop fit-for-purpose solutions for the optimization of bioprocesses for a broad base of host organisms. One grant of up to 150K EUR/year for up to 3 years.
• Innovative approaches to economical remediation of contaminated high volume materials.  Proposals dedicated to the remediation of high-volume, low-contaminated soil and water, with a specific focus on chloro-organic pollutants and particularly those contaminated with hexachlorocyclohexane (HCH).  One grant of up to 150K EUR/year for up to 2 years.
• Condensate-based high-sensitivity cell-free screening assays for the modulation of protein-protein interactions.  One grant of up to 100K EUR/year for up to 3 years.
• Advancing molecule synthesis and discovery – up to 3 grants each comprising a 1-year full Synthia® Retrosynthesis Software license, training, and extensive interaction with our scientists.

www.merckgroup.com/en/research/open-innovation/research-grants.html

Aims to strengthen cooperative research projects that deliberately connect insights from research into common ND’s or age-related processes with NCL research, with a focus on opening new therapeutic avenues that might benefit both conditions.
Funding: €200K
https://www.ncl-stiftung.de/english/what-we-do/

Neurofibromatosis Research Academy – Leadership Award: Supports visionary, established neurofibromatosis investigators with documented history of neurofibromatosis funding, publications, strong mentorship and commitment to leadership to serve as Director and Deputy Director of the Neurofibromatosis Research Academy.

Proposal must address the strategic goal to increase capacity and multi-disciplinary research through support and development of vital resources and the next generation of NF cancer researchers to improve patient care.

Funding: $2.4M up to 4 years.

https://cdmrp.health.mil/funding/nfrp

https://ebrap.org/eBRAP/public/Program.htm

The program aim is to foster outstanding and innovative scientific research – basic, translational, and clinical – by bringing together international teams of researchers with complementary expertise and resources to work together on a common thematic problem. The proposals should aim to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and/or neurovascular disease. Early career investigators play a vital role in these networks, which provide an excellent context for training and career development in cardiovascular and neurovascular research.

Leducq networks (3-6 institutional members) should demonstrate the added value of international collaboration for their research program.

Funding: $9,500,000 over five years.  In the 2026-27 cycle, the Foundation will award four INE grants.

https://www.fondationleducq.org/international-networks-of-excellence-how-to-apply/how-to-apply/

https://www.fondationleducq.org/wp-content/uploads/2025/07/Program-Description-2026.pdf

Concept Award (CA): Supports the exploration of highly innovative new concepts or untested theories that address an important problem relevant to reconstructive transplantation.

Funding: up to $200K for 18 months

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rtrp

These awards will help pioneer and accelerate novel drug development for the treatment of Parkinson’s, providing researchers the opportunity to generate the essential data and help bridge the gaps needed to get their projects/compounds ready to enter full scale drug discovery with an industry partner or the Parkinson’s Virtual Biotech.

Looking for projects that will have a clear focus on translational drug development to make a difference to those affected by Parkinson’s.

Funding: There is no minimum award amount and the maximum award amount is £150,000.

For projects involving in vivo work, an award amount of up to £200,000 will be considered.

Lead PI must be UK based

https://www.parkinsons.org.uk/research/drug-accelerator-awards

The terminal degree or completion of residency must have occurred within ten years prior to the award.

Proposals must focus on research directly related to myotonic dystrophy and may include basic, clinical, or applied research. Eligible research areas include, but are not limited to:

• Pathogenesis of DM
• Molecular mechanisms underlying phenotype differences in DM1, DM2, and congenital DM
• Development of diagnostics or biomarkers
• Studies of disease progression or natural history
• Identification and validation of endpoints for drug development
• Standards of care and care integration, including nursing, social work, and psychology
• Epidemiology, health economics, and patient support services
• Therapeutic development, particularly early-stage projects that could leverage additional funding

Proposals focused on DM2 research are given priority for these awards.

Funding: $190,000 over two years.

https://myotonic.org/research/grants-and-funding/opportunities

https://myotonic.org/wp-content/uploads/MDF_RFA-2027-Early-Career-Grants.pdf

Clinical /Translational Research Award: Supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications.

Funding: up to $1.9M for 4 years

Idea Development Award: Supports the development of impactful, highrisk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD in the near term.

Funding: up to $500K for 2 years

https://cdmrp.health.mil/funding/dmdrp

https://ebrap.org/eBRAP/public/Program.htm

Aiming at supporting fundamental, translational and clinical research programs related to research on intellectual deficiencies of genetic origin
exclusively dedicated to Trisomy 21 research.
Pilot or exploratory grants
For early stage research projects built on preliminary data or small projects that complement larger primary projects.
Funding: 50K EUR for 2 years
Advanced grants
For larger breakthrough projects with substantial preliminary data.
Funding: 80K EUR for 2 years
https://www.research.fondationlejeune.org/call-for-projets/

World-leading innovation grant that supports early-career scientists and physicians to launch their professional journeys in pain research within member countries of the European Pain Federation EFIC®. Directly target clinical and human experimental pain research, including innovative educational initiatives that improve pain diagnosis and treatment.
Funding: max €50K for pup to 2 years
https://www.grunenthal.com/en/world-free-of-pain/initiatives/e-g-g

These grants are awarded to seasoned researchers seeking to make consequential translational discoveries that will drastically alter clinical care for pregnant people and babies, whether through evidence-based prevention, diagnosis, or intervention.

The proposed research should focus on one of these priority topic areas:

1. Spontaneous preterm birth.
2. Cardiovascular health conditions developed during pregnancy or exacerbated during pregnancy

Funding: $200,000 over two years inclusive of 10% indirect costs

https://www.marchofdimes.org/our-work/research/grants-awards/discovery-research-grants

Neurofibromatosis Research Academy – Scholar Award: supports early-career investigators (Scholars) joining the Neurofibromatosis Research Academy to pursue a research project that may include basic, translational, and/or clinical research under the leadership of the NFRA Director and Deputy Director.

Funding: up to $1.2M for 4 years.

Exploration-Hypothesis Development Award: Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research

Funding: up to $160K for 2 years.

Investigator-Initiated Research Award: Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to neurofibromatosis research and/or patient care.

Funding: up to $920K for 3 years.

Synergistic Idea Award: Supports new ideas that represent synergistic approaches to NF research involving two or three PIs.

Investigators are expected to demonstrate the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes will be realized rapidly and efficiently and could not otherwise be accomplished through the independent efforts of a single investigator.

Funding: up to $3.2M for 3 years.

https://cdmrp.health.mil/funding/nfrp

https://ebrap.org/eBRAP/public/Program.htm

A joint effort to stimulate and develop creative, paradigm-shifting ideas in invasive lobular carcinoma (ILC) that have the potential to advance knowledge of lobular breast cancer detection, diagnosis, pathology, treatment, recurrence prevention, or surveillance.
Funding: $50K for 1 year
https://www.aacr.org/grants/aacr-lbca-invasive-lobular-carcinoma-research-challenge-grants/

Drug Development RFP

The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. This funding opportunity concentrates on diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia.

Funding: Up to $5,000,000 based on stage and scope of research. No overhead.
Neuroimaging and CSF Biomarker RFP

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

• Developing novel PET ligands for clinical trials
• Supporting novel CSF biomarkers
• Validating innovative MRI approaches in larger cohorts
• Developing novel measures of functional activity such as EEG

Funding: Up to $600,000 based on stage and scope of research. No overhead.

Prevention RFP
to support precision prevention studies, combination therapy studies, and comparative effectiveness research that probe whether the use or choice of interventions may reduce the risk of Alzheimer’s disease or other dementias. Studies that are not in humans will not be considered.
Funding: up to $5,000,000 for clinical trials based on stage and scope of research. No overhead.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Academy of Kidney Cancer Investigators – Early-Career Scholar Award: Supports impactful kidney cancer research; and integrates new Early-Career Scholars (ECS) into a virtual academy providing intensive mentoring, national networking, research collaborations, and a peer group for early-career kidney cancer investigators

Funding: up to $1.2M for 4 years

Idea Development Award: Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.

Funding: up to $1.2M for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/kcrp

Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to significantly impact ovarian cancer.  • Proposed projects may range from small, proof-of concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1 or 1/2).

Funding: up to $2.8M for 4 years

Ovarian Cancer Academy – Early-Career Investigator Award: Supports the addition of new early career investigators to the unique, interactive, virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.125M for 4 years

Ovarian Cancer Clinical Trial Academy – Early Career Investigator Award:  Supports the addition of new ECIs to the unique, interactive, virtual Clinical Trial Academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.4M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=711101

Focused Pilot Award: Supports the exploration and development of impactful and innovative concepts under a patient centered focus area that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life.

Funding: up to $300K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=707102

Concept Award (CA): Supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers.

Funding: up to $140K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rcrp

Through two prestigious Awards of €200,000 each, Fondation ARC rewards top-class researchers whose careers and work have let to major breakthroughs in cancerology.

www.fondation-arc.org/appels-a-projets/55th-fondation-arc-leopold-griffuel-awards

Melanoma Academy Scholar Award: Supports the addition of Scholars to a virtual academy providing intensive mentoring, national networking, collaborations and a peer group for earlycareer melanoma investigators.

Funding: up to $770K for 3 years

Survivorship Research Award: Supports studies addressing melanomaspecific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners

Funding: up to $1.02M for 3 years

https://cdmrp.health.mil/funding/erp

https://cdmrp.health.mil/funding/default

Funds activities that hold promise of identifying therapies (cures) for paralysis in humans. It has particular focus on placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization.  Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a ‘change of direction’.

Funding: $5K to $75K for 1 year (second year considered, no overhead)

https://mcpf.org/new-investigator-grant-application/

https://mcpf.org/wp-content/uploads/2025/02/MCPF-Research-Guidelines-1.doc

Funds an established, leading PIs pursue a potentially ground-breaking, high-risk project in basic research in ALS.
Funding: 200K CHF (~880,000 NIS) for 2 years (one or two grants will be funded).
https://www.radala-foundation.com/index.html

The Innovator Awards Program enables researchers worldwide to test ideas and collaborate to advance the understanding of IBD. The Foundation encourages applications for high-impact basic and translational research projects that use artificial intelligence (AI), machine learning (ML), big data analytics and various model systems to deepen our understanding of the mechanisms in IBD and accelerate therapeutic discovery in the field.

Funding: Iindividual research projects – up to $150,000;  Collaborative projects involving multiple investigators – up to $300,000. The award period is 12 months.

https://krfoundation.org/grants/funding-opportunities/innovator-awards/

Resource Development Award: Supports the development of a multiomic atlas generated from well-annotated human BMF samples, with omic data derived from marrow specimens

Funding: up to $1.25M for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/bmfrp

This programme funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s. We do not fund research which is directed at symptomatic relief.

For preclinical research, we fund grants up to £250,000 (GBP) and prioritise projects that are likely to lead to clinical trials in people with Parkinson’s within 5 years. For clinical research, we fund clinical trials and sub-studies of trials in people with Parkinson’s. The grant amount is flexible, so please contact us ahead of submission if you are thinking of applying for a clinical trial.

The ‘Research Strategy’ provides more information on the types of research we fund, our funding priorities and how we provide funding.

www.cureparkinsons.org.uk/research/for-researchers/apply-for-funding/quarterly-research-grant

Research Strategy: www.cureparkinsons.org.uk/2025/11/an-update-to-our-research-strategy

Early Investigator Research Award: Supports Parkinson’s disease (PD) research opportunities for investigators in the early stages of their careers; however, the investigator need not have previous Parkinson’s disease research experience.

Funding: up to $1M for 2 years

Investigator-Initiated Research Award: Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to PD research.  • Supports the full spectrum of research from basic pre-clinical science through clinical trials.

Funding: up to $2M for 3 years

https://cdmrp.health.mil/funding/prp

https://ebrap.org/eBRAP/public/Program.htm

Designed to support early-stage, pre-development concepts — innovations that have not yet been built or tested, but that hold the potential to transform the landscape of cancer immunotherapy.
The most competitive applicants will propose innovations that address areas where technological advancement can have the greatest impact on cancer immunotherapy and patient outcomes. Such technologies may include, but are not limited to:
Computational systems biology approaches, Advanced cancer (or molecular) profiling technologies, Real-time visualization technologies, Complex multicellular culture systems and Novel therapeutic technologies.
Funding: seed funding of up to $600K over 2-4 years (10% overhead in addition to awarded funds)
https://www.cancerresearch.org/technology-impact-award

We support innovative basic, translational, and clinical research that advances understanding and care for LGS.
Priority Research Areas: LGS biomarkers that predict disease course and/or treatment response / Mortality in LGS / Medical device use in LGS / Disease-modifying therapies targeted to the LGS Secondary Brain Network / Natural history of LGS / Non-seizure issues & quality of life in LGS / Prevention, reversal, and/or stabilization of LGS / Neurodegeneration in LGS / Pediatric-to-adult transition of care in LGS
Funding: up to $75K over 1–2 years.
www.lgsfoundation.org/365-research-grant
www.lgsfoundation.org/wp-content/uploads/2025/11/RFP_-LOI-and-Full-Proposal-Instructions-.docx.pdf

To provide seed funding for highly innovative research with significant potential to accelerate the mission of the Lustgarten Foundation (Early Detection and Interception, Therapeutic Development, Personalized Medicine).
Preference will be given to proposals addressing understudied and/or poorly understood aspects of pancreatic cancer biology.
Proposals that involve collaborations across groups or that bring new expertise and/or technology into the field will be preferred.
Funding: up to $110K for 1 year
https://lustgarten.org/innovation-collaboration-rfa/

Supports studies that employ CureGN and or NEPTUNE resources to advance clinical and translational research in glomerular disease.  Projects can include, but are not limited to, those that can be used to generate feasibility data to support advancement of promising future studies and projects to develop clinical assays, or protocols, or early phase clinical trials.

Funding: up to $250,000 per project in direct costs only, paid over a 2-year period

https://nephcure.org/about/our-impact/grant-opportunities/

 (Abstracts may be submitted at any time until the closing date)

AOI #20 DRIVe Forward

Aims to develop products, capabilities, and technologies to detect threats, improve patient care, including ancillary supplies and resources, as well as novel approaches to develop, clinically validate, and deploy/distribute MCMs rapidly and agnostically.

Especially interested in proposals that aim to address one or more of the following topics:

1. Microbiome-based therapies
2. Resilience to infection
3. Next-generation vaccines
4. Next-generation therapeutic antibodies
5. Artificial blood products
6. Extremely mobile viral diagnostic platforms for use in extremely remote settings
7. Non-pharmacological approaches for enhanced immunity

Funding: up to $750K.

https://drive.hhs.gov/partner.html

https://drive.hhs.gov/files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_01.pdf

Frontier Grants facilitate transitions from basic research to attractive prospects for biotech investors

Lundbeck Foundation has now introduced Frontier Grants to support critical activities to advance and consolidate basic research projects, with significant potential, into attractive prospects for investors. The purpose of the grant is to advance mature research projects to become financeable and commercially tangible venture opportunities.

Purpose:

A Frontier Grant (FG) provides financial and interactive support to test and develop the commercial and translational potential of a basic research finding together with the researcher and allowing for mentoring and professional development activity.

Criteria – Who can apply:

Field must be within biomedicine or health sciences, i.e., not limited to brain health.

The research must be affiliated with a Danish non-commercial research institution – international collaboration is allowed.

duration of up to 18 months and a max budget of DKK 5.0 M (with optional 2.5 M and +6 months extension).
https://lundbeckfonden.com/apply-grants/frontier-grants

(Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period from the BAA release date to the BAA closing date)

Research Areas of Interest (please see BAA for more details)

1. Damage Control Resuscitation
2. Prolonged Field Care (PFC)
3. Portable Lab Assays and Diagnostics
4. Force Health Protection and Environmental Medicine
5. Brain Health
6. Immune Response
7. Chronic Pain
8. Automation of Systematic Reviews and Metanalysis
9. Medical Simulation and Training Technologies
10. Human Performance Optimization
11. Canine Medicine and Performance

Most projects are anticipated to have a total cost at or below $1,500,000 (including indirect costs). Projects that have a total cost higher than $1,500,000 (including Indirect costs) with outstanding scientific merit that meet a critical need may be accepted; however the total cost of these projects are not to exceed $5,000,000.00 (including Indirect costs).

Duration: up to 5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=549113